Literature DB >> 12394346

Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk?

Hsiao-Yuan Tang1, Eldridge Hutcheson, Susan Neill, Margaret Drummond-Borg, Michael Speer, Raye Lynn Alford.   

Abstract

PURPOSE: To assess the occurrence of two mutations associated with susceptibility to aminoglycoside ototoxicity.
METHODS: Genetic analysis of anonymized, residual diagnostic specimens.
RESULTS: One occurrence of the A1555G mutation and seven occurrences of the 961delT + C(n) nucleotide change were found. Two previously unreported sequence changes, T961G and 956-960insC, were also found in six and five specimens, respectively.
CONCLUSIONS: Genetic susceptibility to aminoglycoside ototoxicity may be more common than previously suspected. Further study of the 961delT + C(n) mutation is recommended to confirm its role in aminoglycoside ototoxicity and assess penetrance and variability with and without exposure to aminoglycoside antibiotics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12394346     DOI: 10.1097/00125817-200209000-00004

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  25 in total

1.  Mutational analysis of the mitochondrial 12S rRNA gene in Chinese pediatric subjects with aminoglycoside-induced and non-syndromic hearing loss.

Authors:  Zhiyuan Li; Ronghua Li; Jianfu Chen; Zhisu Liao; Yi Zhu; Yaping Qian; Sudao Xiong; Selena Heman-Ackah; Jianbo Wu; Daniel I Choo; Min-Xin Guan
Journal:  Hum Genet       Date:  2005-04-20       Impact factor: 4.132

Review 2.  The inner ear and the neurologist.

Authors:  Charlotte Agrup; Michael Gleeson; Peter Rudge
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02       Impact factor: 10.154

3.  Ototoxicity caused by aminoglycosides.

Authors:  Maria Bitner-Glindzicz; Shamima Rahman
Journal:  BMJ       Date:  2007-10-20

4.  Cerebrospinal fluid compartmental pharmacokinetics of amikacin in neonates.

Authors:  K Allegaert; I Scheers; E Adams; G Brajanoski; V Cossey; B J Anderson
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

Review 5.  Gene therapy for muscular dystrophy: moving the field forward.

Authors:  Samiah Al-Zaidy; Louise Rodino-Klapac; Jerry R Mendell
Journal:  Pediatr Neurol       Date:  2014-08-07       Impact factor: 3.372

6.  Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy.

Authors:  Vinod Malik; Louise R Rodino-Klapac; Laurence Viollet; Jerry R Mendell
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

7.  The prevalence of mitochondrial mutations associated with aminoglycoside-induced deafness in ethnic Latvian population: the appraisal of the evidence.

Authors:  Viktorija Igumnova; Lauma Veidemane; Anda Vīksna; Valentina Capligina; Egija Zole; Renate Ranka
Journal:  J Hum Genet       Date:  2018-12-06       Impact factor: 3.172

Review 8.  Pharmacoeconomic evaluations of pharmacogenetic and genomic screening programmes: a systematic review on content and adherence to guidelines.

Authors:  Stefan Vegter; Cornelis Boersma; Mark Rozenbaum; Bob Wilffert; Gerjan Navis; Maarten J Postma
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 9.  PharmGKB summary: very important pharmacogene information for MT-RNR1.

Authors:  Julia M Barbarino; Tracy L McGregor; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-12       Impact factor: 2.089

Review 10.  Applying U.S. national guidelines for ototoxicity monitoring in adult patients: perspectives on patient populations, service gaps, barriers and solutions.

Authors:  Dawn Konrad-Martin; Gayla L Poling; Angela C Garinis; Candice E Ortiz; Jennifer Hopper; Keri O'Connell Bennett; Marilyn F Dille
Journal:  Int J Audiol       Date:  2017-11-20       Impact factor: 2.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.